![](https://testing.innoplexus.com/wp-content/plugins/relevant/images/no_preview.jpg)
Ontosight® – Biweekly NewsletterJune 17th – June 30th, 2024 –Read More
Ontosight® – Biweekly NewsletterJune 17th – June 30th, 2024 –Read More
May 24
Apr 24
Innoplexus wins Horizon Interactive Gold Award for Curia App
Read MoreFrankfurt, Germany; 14 March 2024 Partex Group, a pioneer in AI-driven drug discovery, today announces a collaboration with global pharmaceutical giant Sanofi, aimed at using Partex’s advanced AI technology to enhance the value of Sanofi’s out-licensing portfolio.
Building upon the success of a pilot project conducted in 2022, this new collaboration centers around the expansion of an innovative approach which leverages Partex’s AI arm, Innoplexus, and its proprietary AI technology to identify new indications within Sanofi’s out-licensing portfolio. Through meticulous indication expansion, prioritization, and lab validation studies, the collaboration endeavours to uncover fresh prospects for Sanofi’s out-licensing portfolio.
As a crucial component of this collaboration, Innoplexus will embark on a journey to scan, analyse, and enrich multiple out-licensing asset candidates, spanning therapeutic areas. The overarching vision is to explore avenues for repurposing or repositioning these assets for out-licensing focusing on patients’ needs..
Dr. Gunjan Bhardwaj, CEO of Partex, expresses enthusiasm about this innovative milestone collaboration, stating, “Our collaboration with Sanofi exemplifies our dedication to driving innovation in drug discovery. By harnessing the power of AI, we aspire to unlock the hidden potential within Sanofi’s out-licensing portfolio and bring hope to patients suffering from unmet medical needs. This collaboration is a testament to our shared commitment to advancing healthcare through cutting-edge technology.”
The collaboration is already in motion, with the selection of the first three assets for AI predictions, set to be completed in 2024.
Frankfurt, Germany, 3rd June 2024, 9am CET Partex, a leading provider of AI-driven solutions in the pharmaceutical industry, is thrilled to…
Frankfurt, Germany, 23 April 2024 – Partex, a leading provider of AI-driven solutions in the pharmaceutical industry, is thrilled to…
Frankfurt, Germany; 28 March 2024 – Partex Group, a pioneer in AI-driven drug discovery, announces a collaboration with Althea DRF…
During the German Cancer Congress 2024 in Berlin, the companies Innoplexus AG /Amrit AG, companies of Partex N.V., presented the…
Frankfurt, Germany; 14 March 2024 Partex Group, a pioneer in AI-driven drug discovery, today announces a collaboration with global pharmaceutical…
January 02, 2024 – Innoplexus and Amrit AG, members of the Partex NV Group, providers of innovative technology for health…
Exciting News! Anavex Life Sciences and Partex NV Announce Strategic Partnership to Enhance Patient Experience. Anavex Life Sciences Corp. and Partex NV N.V. Group are pleased to announce…
The treatment and support of patients with advanced tumor diseases is a complex task involving numerous disciplines. For the interdisciplinary…
Artificial Intelligence (AI) pioneer Innoplexus and London based Parametric Insurance start-up, Innovatrix Capital, collaborating upon using AI & Machine Learning…
Innoplexus and Inflection Biosciences enter strategic collaboration based on Artificial Intelligence to expedite PIM kinase inhibitor development ESCHBORN, Germany, May 30,…